Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.19.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Operating expenses:    
Research and development (includes $53,905 IPR&D impairment in 2018) $ 58,572 $ 5,822
General and administrative 4,352 2,440
Total operating expenses 62,924 8,262
Loss from operations (62,924) (8,262)
Other (expense) income:    
Interest expense, net (58) (7)
Other expense (31)
Gain on settlement of mortgage note receivable 106
Loss on disposal of property and equipment, net (60) (100)
Change in fair value of derivative liabilities 306 907
Total other income, net 294 769
Loss before income taxes (62,630) (7,493)
Income tax benefit 13,582 6,880
Net loss $ (49,048) $ (613)
Net loss per common share, basic and diluted $ (1.75) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 28,009,000 24,126,000